相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Anti-CD20 Therapy Acts via FcγRIIIA to Diminish Responsiveness of Human Natural Killer Cells
Cristina Capuano et al.
CANCER RESEARCH (2015)
Mediastinal Burkitt Lymphoma in Childhood
Marta Pillon et al.
PEDIATRIC BLOOD & CANCER (2014)
Improved treatment results of children with B-cell non-Hodgkin lymphoma: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 study
Masahito Tsurusawa et al.
PEDIATRIC BLOOD & CANCER (2014)
Effector mechanisms of anti-CD20 monoclonal antibodies in B cell malignancies
Marcin Okroj et al.
CANCER TREATMENT REVIEWS (2013)
A critical review of the role of Fc gamma receptor polymorphisms in the response to monoclonal antibodies in cancer
James D. Mellor et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy
Divi Cornec et al.
ANNALS OF HEMATOLOGY (2012)
Fc gamma receptor 3a genotype predicts overall survival in follicular lymphoma patients treated on SWOG trials with combined monoclonal antibody plus chemotherapy but not chemotherapy alone
Daniel O. Persky et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcγRllla polymorphism
Yuji Mishima et al.
INTERNATIONAL IMMUNOLOGY (2012)
Fc-Gamma-Receptor IIIa Polymorphism and Gene Expression Profile Do Not Predict the Prognosis in Diffuse Large B-cell Lymphoma Treated with R-CHOP Protocol
Laszlo Varoczy et al.
PATHOLOGY & ONCOLOGY RESEARCH (2012)
The impact of Fc-γ receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab
Manfred Ahlgrimm et al.
BLOOD (2011)
Interindividual Variability of Response to Rituximab: From Biological Origins to Individualized Therapies
Guillaume Cartron et al.
CLINICAL CANCER RESEARCH (2011)
The H/R Fc gamma RIIA-131 polymorphism and survival in patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP: a study in a genetically mixed population
Debora Levy et al.
CLINICS (2011)
Effect of FCGR2A and FCGR3A variants on CLL outcome
David Dornan et al.
BLOOD (2010)
Phase II Window Study on Rituximab in Newly Diagnosed Pediatric Mature B-Cell Non-Hodgkin's Lymphoma and Burkitt Leukemia
Andrea Meinhardt et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98
Giovanni Martinelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
FCGR3A-158V/F polymorphism may correlate with the levels of immunoglobulin in patients with non-Hodgkin's lymphoma after rituximab treatment as an adjuvant to autologous stem cell transplantation
Mitsufumi Nishio et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2009)
Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study
Mary Gerrard et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
FcγRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients
Marcia Paiva et al.
CANCER GENETICS AND CYTOGENETICS (2008)
Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma
Nancy M. Pennell et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
FcγRIIIA and FcγRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Emanuela Carlotti et al.
HAEMATOLOGICA (2007)
FCγRIIIA and FCγRIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Zdravko Mitrovic et al.
HAEMATOLOGICA (2007)
The efficacy of rituximab plus Hyper-CVAD regimen in mantle cell lymphoma is independent of FCγRIIIa and FCγRIIa polymorphisms
S. Galimberti et al.
JOURNAL OF CHEMOTHERAPY (2007)
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents
Mitchell S. Cairo et al.
BLOOD (2007)
Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients
Catherine Patte et al.
BLOOD (2007)
FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma
Dong Hwan Kim et al.
BLOOD (2006)
Single agent rituximab in patients with follicular or mantle cell lymphoma:: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system:: a study of the Swiss Group for Clinical Cancer Research (SAKK)
A Ghielmini et al.
ANNALS OF ONCOLOGY (2005)
The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95
W Woessmann et al.
BLOOD (2005)
Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy
Q Gong et al.
JOURNAL OF IMMUNOLOGY (2005)
FcγRIIIa and Fc-γRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia
SS Farag et al.
BLOOD (2004)
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
O Manches et al.
BLOOD (2003)
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
WK Weng et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
G Cartron et al.
BLOOD (2002)
分享论文
